As private credit financing expands across life sciences, lenders must look beyond traditional underwriting considerations to account for regulatory uncertainty, the growing significance of data and technology-driven assets, and the changing nature of collateral value. These developments require a more sophisticated approach to diligence and loan documentation. This article examines key regulatory and market trends affecting life sciences borrowers, explores why intellectual property has become a more dynamic component of credit analysis, and highlights practical considerations for structuring loan documents to better protect lenders in today's environment.

Reproduced with permission. Originally published August 5, 2026, "Emerging considerations for loan documents in life sciences,” Reuters Legal News.